SimonMed Imaging Implements the First FDA-Cleared 3D Tomosynthesis Software Using Artificial Intelligence
iCAD’s Innovative ProFound
AI™ Solution for Digital Breast Tomosynthesis offers high-performing workflow
solution for radiologists
PHOENIX and NASHUA, N.H. (July
10, 2019) – SimonMed Imaging, one of the largest outpatient medical imaging providers and
largest physician radiology practices in the United States, announced today
their implementation of the first FDA-cleared AI program for significantly
enhancing early breast cancer detection for 3D mammography. The AI program,
called ProFound AI™ for digital breast tomosynthesis (DBT), is a technology
developed by iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions.
ProFound AI for DBT
is a high-performance, deep learning, workflow solution that assists radiologists
reading mammography. It is the first and only FDA cleared 3D tomosynthesis
technology using artificial intelligence.
“Implementing
ProFound AI into our processes for breast cancer screenings will improve detection
of breast cancer and reduction of false positives and recalls,” said John Simon, M.D., Founder and CEO of SimonMed. “With
the enhanced technology available through 3D mammography, the review of the 84
slices of breast tissue per breast will now be expedited, but does not replace the specialized radiologist.”
ProFound
AI for DBT was FDA-cleared in 2018 and offers benefits to both radiologists and
patients alike. Designed to detect malignant soft-tissue densities and
calcifications, the software provides radiologists with key data, such as Certainty
of Findings and Case Scores, which can assist radiologists in making
clinical decisions and prioritizing caseloads. The technology has been
clinically proven to improve cancer detection rates by 8 percent,
reduce unnecessary patient recall rates by 7.2 percent, and slash radiologists’ reading time by 52.7 percent and up to 57.4 percent
for dense breast 3D image analysis.
“It is exciting
to see the momentum generated following the FDA clearance of ProFound AI for
DBT and the expansion of our marketplace throughout the SimonMed Imaging
enterprise,” said Michael Klein, CEO of iCAD. “This important partnership
demonstrates the need for innovative, advanced AI platform solutions to
assist radiologists in accurately identifying breast cancer sooner, when it may
be more easily treated. SimonMed’s unique nationwide enterprise care
model also provides a scalable platform and partnership
for future collaboration.”
SimonMed
Imaging and its affiliates have been serving local communities throughout the
U.S. for over 30 years, with more than 150 convenient locations to accommodate
patients. Patients interested in learning more can call or text SimonMed at
1-866-614-8555 to schedule an appointment. For more information about ProFound
AI, visit www.icadmed.com
or www.simonmed.com.
About SimonMed
SimonMed Imaging
is the largest physician owned outpatient radiology practice in the United
States and specializes in all major medical fields of medical imaging. Our
vision is to change the medical imaging experience with advanced technology,
and our mission is to provide high quality, affordable medical imaging to all.
The expertise of our physicians, technologists, scientists and advanced
technology leads to more accurate and early reporting. We offer multiple
convenient locations, broad health plan access, and low out-of-pocket costs.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical
technology leader providing innovative cancer detection and therapy solutions.
For more information, visit www.icadmed.com.
“Safe Harbor” Statement under the Private Securities
Litigation Reform Act of 1995
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the
impact of supply and manufacturing constraints or difficulties, uncertainty of
future sales levels, protection of patents and other proprietary rights, the
impact of supply and manufacturing constraints or difficulties, product market
acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or
other reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the economy or
markets served by the Company; and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Media Contacts:
SimonMed Imaging:
Lauren Strait, (480) 998-2600
iCAD:
Jessica Burns, (623) 203-7270
Investor
Relations:
LifeSci
Advisors, Inc.
Jeremy
Feffer, (212) 915-2568